menu
    • menu

    Company profile for AlveoGene

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington, and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). AlveoGene has secured an exclusive license to a proprietary and validated next-generation lentiviral delivery platform developed by the GTC f...
    AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington, and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). AlveoGene has secured an exclusive license to a proprietary and validated next-generation lentiviral delivery platform developed by the GTC for the treatment of respiratory diseases with high unmet needs (excluding the use of the CFTR gene which is mutated in cystic fibrosis).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlveoGeneunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    46 Woodstock Rd, Oxford OX2 6HT
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alveogene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alveogene/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AlveoGene’s Inhaled Therapy AVG-002 Gets FDA Orphan Designation
    AlveoGene’s Inhaled Therapy AVG-002 Gets FDA Orphan Designation

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990299/0/en/AlveoGene-s-Novel-Inhaled-Gene-Therapy-AVG-002-Receives-Orphan-Drug-Designation-from-FDA-for-Lethal-Neonatal-Surfactant-Protein-B-SP-B-Deficiency.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share
    AlveoGene Gets FDA Rare Pediatric Disease Designation for AVG-002
    AlveoGene Gets FDA Rare Pediatric Disease Designation for AVG-002

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2981801/0/en/AlveoGene-Receives-Rare-Pediatric-Disease-Designation-RPDD-from-FDA-for-AVG-002-its-Novel-Inhaled-Gene-Therapy-for-Lethal-Neonatal-Surfactant-Protein-B-SP-B-Deficiency.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    AlveoGene Launches to Develop Unique Inhaled Gene Therapies
    AlveoGene Launches to Develop Unique Inhaled Gene Therapies

    14 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/14/2742984/0/en/AlveoGene-Launches-to-Develop-Unique-Inhaled-Gene-Therapies-for-Rare-Respiratory-Disorders.html

    GLOBENEWSWIRE
    14 Sep 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search